0000000000124541

AUTHOR

Nadia Caruso

showing 2 related works from this author

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After All…

2020

Currently, the prognosis of Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients relapsing after an allogenic hematopoietic stem cell transplantation (allo-SCT) remains poor, with few therapeutic options available. Here we present the case of a 32 years old patient with dasatinib-resistant post-transplant molecular relapse of ALL, who received, as second-line therapy, the combination of ponatinib and donor lymphocyte infusion (DLI). The therapy was safe and the patient achieved a sustained minimal residual disease negative disease, still ongoing after 22 months, which was accompanied by several changes in the immune populations distribution within the bone marrow (i.e., the increase in the C…

0301 basic medicineOncologymedicine.medical_specialtyCancer Researchmedicine.medical_treatmentT lymphocytesCase ReportHematopoietic stem cell transplantationlcsh:RC254-282Donor lymphocyte infusionbone marrow microenviroment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineacute lymhoblastic leukemiaInternal medicinehemic and lymphatic diseasesT lymphocytemedicineponatinibbusiness.industryPonatinibDonor Lymphocyteslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDasatinib030104 developmental biologymedicine.anatomical_structurechemistryOncology030220 oncology & carcinogenesisdonor lymphocyte infusion (DLI)Bone marrowStem cellbusinessCD8medicine.drugFrontiers in Oncology
researchProduct

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques

2015

Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson (ABL) and breakpoint cluster region (BCR) genes. The resulting BCR-ABL1 oncogene leads to increased proliferation and survival of leukemic cells. Successful treatment of CML has been accompanied by steady improvements in our capacity to accurately and sensitively monitor therapy response. Currently, measurement of BCR-ABL1 mRNA transcript levels by real-time quantitative PCR (RQ-PCR) defines critical response endpoints. An antibody-based technique for BCR-ABL1 protein recognition could be an attractive alternative to RQ-PCR. To date, there have been no studies evaluating whether flow-cytometr…

Genetics and Molecular Biology (all)medicine.medical_specialtyScienceFusion Proteins bcr-ablBiologyBiochemistryPolymerase Chain ReactionInternal medicinehemic and lymphatic diseasesmedicineHumansAgricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)In Situ Hybridization FluorescenceImmunoassayMultidisciplinaryABLHematologymedicine.diagnostic_testMedicine (all)QRbreakpoint cluster regionMyeloid leukemiaLeukemia Myelomonocytic Chronicmedicine.diseaseFlow CytometryMolecular biologyFusion proteinLeukemiaReal-time polymerase chain reactionAgricultural and Biological Sciences (all)ImmunoassayMedicineResearch ArticlePLoS ONE
researchProduct